Hepatitis C Infection and Chronic Renal Diseases: A Systematic Review
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
A connection was reported between hepatitis C virus (HCV) and chronic kidney disease (CKD). A viral infection can be both a cause and a consequence of CKD. HCV infection is associated with a greater incidence of diabetes mellitus and CKD and a higher risk of systemic (particularly cardiovascular) effects because HCV infection increases the chance of illness developing. Although the fundamental symptom of HCV-induced glomerulonephritis has been well documented, the virus has been related to CKD in various ways, i.e., new evidence points to a connection between HCV infection and CKD onset, as well as the rapid advancement of CKD to end-stage renal disease, which calls for kidney transplantation or hemodialysis. An HCV infection dramatically increased a person's risk of developing CKD, which can lead to kidney failure. Compared with patients with HCV infection and existing CKD, those with HCV infection who had normal renal function had greater odds of renal progression. The administration of anti-hepatitis medication can result in variations in the estimated glomerular filtration rate, which can either lead to an improvement or a worsening of the patient's health, depending on which direction the variation goes.
Abstract
A connection was reported between hepatitis C virus (HCV) and chronic kidney disease (CKD). A viral infection can be both a cause and a consequence of CKD. HCV infection is associated with a greater incidence of diabetes mellitus and CKD and a higher risk of systemic (particularly cardiovascular) effects because HCV infection increases the chance of illness developing. Although the fundamental symptom of HCV-induced glomerulonephritis has been well documented, the virus has been related to CKD in various ways, i.e., new evidence points to a connection between HCV infection and CKD onset, as well as the rapid advancement of CKD to end-stage renal disease, which calls for kidney transplantation or hemodialysis. An HCV infection dramatically increased a person's risk of developing CKD, which can lead to kidney failure. Compared with patients with HCV infection and existing CKD, those with HCV infection who had normal renal function had greater odds of renal progression. The administration of anti-hepatitis medication can result in variations in the estimated glomerular filtration rate, which can either lead to an improvement or a worsening of the patient's health, depending on which direction the variation goes.
참고문헌 (28)
- World Health Organization, "Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection", World Health Organization, ~ (2018)
- Veit O, "Manson's tropical diseases 23rd edition", Travel Med Infect Dis, 13, pp.117~ (2015)
- Mohanty A, "Impact of direct acting antiviral agent therapy upon extrahepatic manifestations of hepatitis C virus infection", Curr HIV, 2019, pp.16, 389~394
- Stanaway JD, "The global burden of viral hepatitis from 1990 to 2013 : findings from the Global Burden of Disease Study 2013", Lancet(London, England), 388, pp.1081~1088 (2016)
- Ferri C, "Hepatitis C virus syndrome: A constellation of organ- and non-organ specific autoimmune disorders, B-cell non-Hodgkin's lymphoma, and cancer", World J Hepatol, 7, pp.327~343 (2015)
- Ladino M, "Hepatitis C virus infection in chronic kidney disease", J Am Soc Nephrol, 27, pp.2238~2246 (2016)
- Pol S, "Hepatitis C virus and the kidney", Nat Rev Nephrol, 15, pp.73~86 (2019)
- Trinchet JC, "Complications and competing risks of death in compensated viral cirrhosis(ANRS CO12 CirVir prospective cohort)", Hepatology, 62, pp.737~750 (2015)
- Mostafa A, "Hepatitis C infection and clearance : impact on atherosclerosis and cardiometabolic risk factors", Gut, 59, pp.1135~1140 (2010)
- Singhal A, "Regulation of insulin resistance and type II diabetes by hepatitis C virus infection : A driver function of circulating miRNAs", J Cell Mol Med, 22, pp.2071~2085 (2018)
- Saxena V, "Safety and efficacy of current directacting antiviral regimens in kidney and liver transplant recipients with hepatitis C : Results from the HCV-TARGET study", Hepatology, 66, pp.1090~1101 (2017)
- Maan R, "The frequency of acute kidney injury in patients with chronic hepatitis C virus infection treated with sofosbuvir-based regimens", Aliment Pharmacol Ther, 46, pp.46~55 (2017)
- Zhang H, "Association of hepatitis C and B virus infection with CKD and impact of hepatitis C treatment on CKD", Sci Rep, 9, pp.1910~ (2019)
- Hsu CK, "Renal function trajectories in hepatitis C infection : differences between renal healthy and chronic kidney disease individuals", Sci Rep, 11, pp.17197~ (2021)
- Park H, "Chronic hepatitis C virus(HCV)increases the risk of chronic kidney disease(CKD)while effective HCV treatment decreases the incidence of CKD", Hepatology, 67, pp.492~504 (2018)
- Chen YC, "A Taiwanese nationwide cohort study shows interferon-based therapy for chronic hepatitis C reduces the risk of chronic kidney disease", Medicine(Baltimore), 94, pp.e1334~ (2015)
- Liu CH, "Evolution of eGFR in chronic HCV patients receiving sofosbuvir-based or sofosbuvir-free direct-acting antivirals", J Hepatol, 72, pp.839~846 (2020)
- Sise ME, "Direct-acting antiviral therapy slows kidney function decline in patients with hepatitis C virus infection and chronic kidney disease", Kidney Int, 97, pp.193~201 (2020)
- Chen H, "Efficacy and safety of anticoagulation in more advanced portal vein thrombosis in patients with liver cirrhosis", Eur J Gastroenterol Hepatol, 28, pp.82~89 (2016)
- Azmi AN, "Hepatitis C and kidney disease : An overview and approach to management", World J Hepatol, 7, pp.78~92 (2015)
- Bonetto S, "Recent advances in the treatment of irritable bowel syndrome", Pol Arch Intern Med, 131, pp.709~715 (2021)
- Molnar MZ, "Association of hepatitis C viral infection with incidence and progression of chronic kidney disease in a large cohort of US veterans", Hepatology, 61, pp.1495~1502 (2015)
- Dai CY, "Chronic hepatitis C infection is associated with insulin resistance and lipid profiles", J Gastroenterol Hepatol, 30, pp.879~884 (2015)
- Sethi S, "Membranoproliferative glomerulonephritis-a new look at an old entity", N Engl J Med, 366, pp.1119~1131 (2012)
- Ozkok A, "Hepatitis C virus associated glomerulopathies", World J Gastroenterol, 20, pp.7544~7554 (2014)
- Azmi AN, "Hepatitis C and kidney disease : An overview and approach to management", World J Hepatol, 7, pp.78~92 (2015)
- Angulo-Diaz V, "Management of chronic hepatitis C in end-stage renal disease", J Clin Gastroenterol, 52, pp.287~294 (2018)
- Gupta SK, "Single-dose pharmacokinetics and safety of pegylated interferon-alpha2b in patients with chronic renal dysfunction", J Clin Pharmacol, 42, pp.1109~1115 (2002)